前列腺癌核醫診斷市場：以放射性藥物、診斷方法、適應症和最終用戶分類－2026-2032年全球市場預測

預計到 2032 年，攝護腺癌核醫診斷市場將成長至 31.2 億美元，複合年成長率為 13.17%。

主要市場統計數據
基準年 2025	13.1億美元
預計年份：2026年	14.9億美元
預測年份 2032	31.2億美元
複合年成長率 (%)	13.17%

核子醫學在診斷前列腺癌方面正從一種專門的影像技術轉變為腫瘤學中的核心臨床決策工具。正子斷層掃描（PET）和單光子發射斷層掃描（SPECT）為此領域提供了支持，它們可用於識別病灶、表徵復發、確定放射性配體治療的適用性以及提高分期的可靠性。全球前列腺癌的高發生率進一步推動了這項需求。根據國際癌症研究機構（IARC）2022年全球前列腺癌監測網路（GLOBOCAN）的估計，全球每年新增前列腺癌病例超過146萬例，使其成為男性最常見的癌症之一。

PSMA靶向PET成像技術是推動其發展的關鍵因素。在許多臨床場景中，特別是在生化復發和高風險原發病灶的分期方面，使用鎵-68和氟-18的PSMA放射性追蹤劑比傳統CT、骨骼掃描或早期的膽鹼類顯像技術具有更高的病灶檢出率。隨著PSMA-PET在主要腫瘤學、泌尿系統和核子醫學機構的指南中得到日益廣泛的認可，醫療系統正優先發展迴旋加速器能力、發生器使用權、放射性藥物網路以及PET/CT一體化工作流程。

一場將改變我們診斷方式的改變。

我們的診斷方式正在發生變革，從以解剖主導的成像轉向分子層面的特異性診斷。 PSMA PET/CT 即使在腫瘤負荷較低的情況下也能識別淋巴結、骨骼和軟組織中的病灶，從而實現更早的治療決策和更精準的患者篩選，進而拓展其應用範圍。此外，氟-18 示蹤劑的半衰期更長，在許多情況下可以比鎵-68 覆蓋更大的區域，從而改變藥物的給藥經濟性。

人工智慧（AI）的累積影響

人工智慧 (AI) 正在逐步改變核子醫學診斷中前列腺癌的影像擷取、解讀和操作。 AI 驅動的影像重建可以降低影像噪聲，並且在與本地規範檢驗後，可望縮短掃描時間並降低輻射劑量。電腦輔助病灶檢測、自動分割、SUV 定量和全身腫瘤負荷測量正在提高 PSMA PET 工作流程的可重複性。

主要市場的關鍵區域洞察

北美仍然是前列腺癌核醫學診斷領域的領先地區，這得益於FDA已通過核准的PSMA-PET顯像劑、較高的PET/CT普及率、強大的核醫學學術計畫以及完善的醫保報銷系統。在美國，隨著多種PSMA標靶示蹤劑的核准，PET/CT的普及速度正在加速。同時，加拿大受益於集中化的癌症診療網路和各省不斷擴大的醫療服務覆蓋範圍，但不同地區的醫療資源仍存在差異。

戰略市場優先排序的關鍵群體洞察

儘管東協地區的醫療衛生體係正在快速現代化，但其核子醫學基礎設施發展並不均衡。新加坡、泰國、馬來西亞、印尼、越南和菲律賓在PET/CT的普及、示踪劑供應和保險報銷方面進展緩慢。海灣合作理事會（GCC）是最具吸引力的高投資叢集之一，沙烏地阿拉伯、阿拉伯聯合大公國、卡達、科威特、巴林和阿曼正在擴大其癌症中心、放射科基礎設施並增加專業醫療人員。

來自主要國家對前列腺癌影像檢查需求的見解。

美國是前列腺癌核醫學診斷領域商業性，這得益於FDA批准PSMA PET造影劑、較高的臨床認知度、PET/CT的廣泛普及以及公立和私立保險公司的積極參與。加拿大正透過癌症機構主導的模式和省級途徑擴大醫療服務的覆蓋範圍，而墨西哥的私立醫院網路和主要都會區的需求也在不斷成長。巴西是拉丁美洲最大的核子醫學診斷國家，聖保羅等主要城市均提供先進的PET服務。

為行業領導者提供的實用建議

產業領導者應優先考慮放射性藥物的擴充性供應，包括多樣化的同位素來源、檢驗的低溫運輸物流，以及與迴旋加速器營運商、發生器供應商和當地放射性藥物藥局建立合作關係。商業性成功越來越依賴可靠的當日供應、標準化的品管、遵守輻射安全標準以及與PET/CT科室清晰的預約協調。

調查方法與證據框架

本執行摘要基於二手研究和市場情報分析方法，並採用三角測量法，適用於醫療技術和放射性藥物的分析。證據來源包括公開的監管記錄、腫瘤學和核子醫學指南、同行評審的臨床文獻、癌症流行病學資料庫、政府衛生統計數據、報銷標準以及放射性藥物的取得指標。

結論與策略展望

在PSMA靶向成像、PET基礎設施的擴展、放射治療與診斷的整合以及精準腫瘤學需求的日益成長的推動下，前列腺癌核醫學診斷正進入持續擴張階段。該領域的發展不再僅僅取決於檢測數量，而是越來越受到示蹤劑物流、實證臨床路徑、定量成像和多學科協作的影響。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席主管觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 市場動態
• 波特五力分析
• PESTLE分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：攝護腺癌核醫診斷市場：依放射性藥物分類

• 11C 科林
• 18F DcfpyL
• 18F 全環蛋白
• 68Ga PSMA
• 新興藥物
  • 18F PSMA 1007
  • 64Cu PSMA

第8章：攝護腺癌核醫診斷市場：依模式分類

• PET
  • 數字PET
  • Time Of Flight PET
• SPECT
  • 常規SPECT
  • SPECT-CT

第9章：攝護腺癌核醫診斷市場：依適應症分類

• 生化復發檢測
• 早期分類
• 治療監測

第10章：攝護腺癌核子醫學診斷市場：依最終用戶分類

• 學術研究機構
• 診斷中心
• 醫院

第11章：攝護腺癌核醫診斷市場：依地區分類

• 亞太地區
• 北美洲
• 拉丁美洲
• 歐洲
• 中東
• 非洲

第12章：攝護腺癌核子醫學診斷市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第13章：攝護腺癌核子醫學診斷市場：依國家分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第14章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年

第15章：公司簡介

• Bayer AG
• Blue Earth Diagnostics Ltd.
• Cardinal Health, Inc.
• Curium Pharma
• Eckert & Ziegler SE
• GE HealthCare Technologies Inc.
• IBA Radiopharma Solutions
• Jubilant Pharmova Limited
• Lantheus Holdings, Inc.
• Novartis AG
• Siemens Healthineers AG
• Telix Pharmaceuticals Limited

The Prostate Cancer Nuclear Medicine Diagnostics Market is projected to grow by USD 3.12 billion at a CAGR of 13.17% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.31 billion
Estimated Year [2026]	USD 1.49 billion
Forecast Year [2032]	USD 3.12 billion
CAGR (%)	13.17%

Prostate cancer nuclear medicine diagnostics are moving from a specialist imaging option to a core clinical decision tool in oncology. The field is anchored by positron emission tomography and single-photon emission computed tomography used to localize disease, characterize recurrence, guide radioligand therapy eligibility, and improve confidence in staging. Demand is reinforced by the global prostate cancer burden; IARC GLOBOCAN 2022 estimated more than 1.46 million new prostate cancer cases worldwide, making it one of the most frequently diagnosed cancers in men.

PSMA-targeted PET imaging has become the defining growth catalyst. Gallium-68 and fluorine-18 PSMA radiotracers have demonstrated higher lesion detection than conventional CT, bone scan, or older choline-based imaging in many clinical scenarios, particularly biochemical recurrence and high-risk primary staging. As guidelines from major oncology, urology, and nuclear medicine bodies increasingly recognize PSMA PET, healthcare systems are prioritizing cyclotron capacity, generator access, radiopharmacy networks, and integrated PET/CT workflows.

Transformative Shifts in the Diagnostic Landscape

The landscape is being reshaped by the transition from anatomy-led imaging to molecular, target-specific diagnostics. PSMA PET/CT is expanding because it can identify nodal, bone, and soft-tissue disease at low tumor burden, supporting earlier treatment decisions and more precise patient selection. Fluorine-18 tracers are also changing distribution economics because their longer half-life enables broader regional delivery than gallium-68 in many settings.

Another major shift is the diagnostic-therapeutic convergence between PSMA imaging and radioligand therapy. Nuclear medicine departments are increasingly positioned within prostate cancer tumor boards, where imaging results influence surgery, radiation planning, systemic therapy sequencing, and theranostic eligibility. This integration is pushing hospitals, imaging technology providers, and radiopharmaceutical developers to build scalable quality systems, standardized interpretation protocols, and resilient isotope supply chains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to alter how prostate cancer nuclear medicine diagnostics are acquired, interpreted, and operationalized. AI-enabled reconstruction can reduce image noise and may support shorter scan times or lower administered activity when validated under local protocols. Computer-aided lesion detection, automated segmentation, SUV quantification, and whole-body tumor burden measurement are improving reproducibility in PSMA PET workflows.

The cumulative impact is strongest when AI connects imaging with clinical context. Radiomics and machine learning models are being evaluated to predict disease aggressiveness, therapy response, and progression risk by combining PET signal, CT or MRI features, PSA kinetics, Gleason score, and treatment history. Industry leaders should treat AI as a regulated clinical decision-support layer, requiring transparent validation, bias monitoring, cybersecurity controls, and integration with PACS, RIS, oncology information systems, and electronic health records.

Key Regional Insights Across Major Markets

North America remains a leading region for prostate cancer nuclear medicine diagnostics due to FDA-cleared PSMA PET agents, high PET/CT installed capacity, strong academic nuclear medicine programs, and established reimbursement pathways. The United States has accelerated adoption through multiple approved PSMA-targeted tracers, while Canada benefits from centralized cancer care networks and growing provincial access, although availability still varies by geography.

Europe is a mature and innovation-rich region, supported by early PSMA PET adoption, strong university hospital infrastructure, and coordinated clinical research. The European Union benefits from cross-border regulatory harmonization, while the United Kingdom, Germany, France, Italy, and Spain continue to expand evidence-based use in staging and recurrence. Asia-Pacific is one of the fastest-evolving opportunity areas, with Japan, Australia, South Korea, China, and India investing in PET capacity, cyclotron networks, and oncology diagnostics to address rising cancer demand and aging-population needs.

Latin America is gaining momentum through Brazil and Mexico, where major urban centers are adopting PET-based prostate cancer imaging despite uneven reimbursement and radiopharmaceutical access. The Middle East, particularly GCC health systems, is investing in premium oncology infrastructure, specialist hospitals, and medical tourism-ready diagnostics. Africa remains underpenetrated, with access concentrated in select centers such as South Africa and North African urban hubs, creating long-term demand for regional radiopharmacy development, workforce training, and public-private investment.

Key Group Insights for Strategic Market Prioritization

ASEAN is characterized by rapid healthcare modernization but uneven nuclear medicine capacity, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines moving at different speeds in PET/CT access, tracer supply, and reimbursement. The GCC is one of the most attractive high-investment clusters because Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman are expanding oncology centers, radiology infrastructure, and specialist medical workforce capacity.

The European Union offers a strong platform for standardized adoption because regulatory alignment, multicenter trials, and nuclear medicine society-led clinical practice norms support scalable PSMA PET implementation. BRICS markets combine large prostate cancer patient populations with diverse infrastructure maturity: China and India are expanding quickly, Brazil and Russia have regional centers of excellence, and South Africa provides an important gateway for African nuclear medicine development.

G7 countries represent the deepest commercial base, with high diagnostic spending, advanced PET infrastructure, and strong pharmaceutical innovation in the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom. NATO countries add relevance through resilient medical isotope supply chains, radiological safety standards, interoperable health systems, and public-sector hospital networks that can influence procurement and emergency preparedness in nuclear medicine.

Key Country Insights for Prostate Cancer Imaging Demand

The United States is the most commercially advanced country for prostate cancer nuclear medicine diagnostics, supported by FDA approvals for PSMA PET agents, high clinical awareness, broad PET/CT availability, and strong private and public payer engagement. Canada is expanding access through cancer agency-led models and provincial pathways, while Mexico is developing demand in private hospital networks and major metropolitan centers. Brazil leads Latin American scale, with Sao Paulo and other large cities supporting advanced PET services.

In Europe, the United Kingdom is strengthening PSMA PET use through specialist cancer pathways, Germany remains a global leader in nuclear medicine research and theranostics, and France benefits from sophisticated academic hospital networks. Italy and Spain continue to increase utilization in recurrence and staging, while Russia maintains PET infrastructure in major cities despite broader market constraints.

China is expanding PET/CT capacity and domestic radiopharmaceutical capabilities, while India offers high-volume long-term potential as oncology infrastructure grows beyond major cities. Japan benefits from advanced imaging quality standards and aging-population demand, Australia is a strong early adopter of PSMA PET evidence generation, and South Korea combines high technology adoption with sophisticated hospital systems and strong oncology diagnostics capacity.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize scalable radiopharmaceutical access, including diversified isotope sourcing, validated cold-chain logistics, and partnerships with cyclotron operators, generator suppliers, and regional radiopharmacies. Commercial success increasingly depends on reliable same-day availability, standardized quality control, radiation safety compliance, and clear scheduling integration with PET/CT departments.

Providers and manufacturers should build evidence packages that connect PSMA PET results to measurable outcomes such as reduced unnecessary procedures, improved radiation planning, earlier recurrence detection, and better selection for radioligand therapy. Organizations should also invest in clinician education for urologists, radiation oncologists, medical oncologists, and nuclear medicine physicians to accelerate appropriate referrals.

Technology providers should embed AI-enabled quantification, structured reporting, and interoperability into imaging platforms while ensuring compliance with medical device regulations and data privacy rules. Market entrants should tailor pricing, reimbursement, and distribution strategies by country maturity rather than applying a single global launch model.

Research Methodology and Evidence Framework

This executive summary is based on triangulated secondary research and market intelligence methods suitable for healthcare technology and radiopharmaceutical analysis. The evidence base includes publicly available regulatory records, oncology and nuclear medicine guidelines, peer-reviewed clinical literature, cancer epidemiology databases, government health statistics, reimbursement references, and radiopharmaceutical access indicators.

Data validation relies on cross-checking clinical adoption signals against tracer approvals, PET infrastructure availability, radiopharmacy capabilities, guideline inclusion, and regional oncology investment trends. Qualitative interpretation is supported by analysis of hospital workflow requirements, isotope logistics, competitive positioning, payer considerations, and regulatory requirements. Findings are framed to support strategic planning and should be periodically updated as approvals, reimbursement policies, and clinical evidence evolve.

Conclusion and Strategic Outlook

Prostate cancer nuclear medicine diagnostics are entering a sustained expansion phase driven by PSMA-targeted imaging, growing PET infrastructure, radiotheranostic integration, and rising demand for precision oncology. The sector is no longer defined only by scan volume; it is increasingly shaped by tracer logistics, evidence-based clinical pathways, quantitative imaging, and multidisciplinary adoption.

Organizations that combine dependable radiopharmaceutical supply, regulatory-grade data, AI-enabled workflow efficiency, and region-specific commercialization will be best positioned to capture value. As prostate cancer care shifts toward earlier detection of actionable disease and better treatment personalization, nuclear medicine diagnostics will remain a strategic pillar of the global oncology ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Prostate Cancer Nuclear Medicine Diagnostics Market, by Radiopharmaceutical

• 7.1. 11C Choline
• 7.2. 18F DcfpyL
• 7.3. 18F Fluciclovine
• 7.4. 68Ga Psma
• 7.5. Emerging Agents
  • 7.5.1. 18F Psma 1007
  • 7.5.2. 64Cu Psma

8. Prostate Cancer Nuclear Medicine Diagnostics Market, by Modality

• 8.1. Pet
  • 8.1.1. Digital Pet
  • 8.1.2. Time Of Flight Pet
• 8.2. Spect
  • 8.2.1. Conventional Spect
  • 8.2.2. Spect Ct

9. Prostate Cancer Nuclear Medicine Diagnostics Market, by Indication

• 9.1. Biochemical Recurrence Detection
• 9.2. Initial Staging
• 9.3. Treatment Monitoring

10. Prostate Cancer Nuclear Medicine Diagnostics Market, by End User

• 10.1. Academic Research Institute
• 10.2. Diagnostic Center
• 10.3. Hospital

11. Prostate Cancer Nuclear Medicine Diagnostics Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Prostate Cancer Nuclear Medicine Diagnostics Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Prostate Cancer Nuclear Medicine Diagnostics Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Bayer AG
• 15.2. Blue Earth Diagnostics Ltd.
• 15.3. Cardinal Health, Inc.
• 15.4. Curium Pharma
• 15.5. Eckert & Ziegler SE
• 15.6. GE HealthCare Technologies Inc.
• 15.7. IBA Radiopharma Solutions
• 15.8. Jubilant Pharmova Limited
• 15.9. Lantheus Holdings, Inc.
• 15.10. Novartis AG
• 15.11. Siemens Healthineers AG
• 15.12. Telix Pharmaceuticals Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
• FIGURE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, RESEARCH DESIGN
• FIGURE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
• FIGURE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, DATA TRIANGULATION
• FIGURE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025 VS 2032 (%)
• FIGURE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025 VS 2032 (%)
• FIGURE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
• FIGURE 13. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
• FIGURE 15. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
• FIGURE 17. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 18. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
• FIGURE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 20. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
• FIGURE 21. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL 11C CHOLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL 11C CHOLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL 11C CHOLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL 18F DCFPYL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL 18F DCFPYL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL 18F DCFPYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL 18F FLUCICLOVINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL 18F FLUCICLOVINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL 18F FLUCICLOVINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL 68GA PSMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL 68GA PSMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL 68GA PSMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL EMERGING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL EMERGING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL EMERGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL 18F PSMA 1007 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL 18F PSMA 1007 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL 18F PSMA 1007 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL 64CU PSMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL 64CU PSMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL 64CU PSMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL PET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL PET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL PET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL DIGITAL PET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL DIGITAL PET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL DIGITAL PET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL TIME OF FLIGHT PET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL TIME OF FLIGHT PET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL TIME OF FLIGHT PET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL SPECT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL SPECT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL SPECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL CONVENTIONAL SPECT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL CONVENTIONAL SPECT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL CONVENTIONAL SPECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL SPECT CT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL SPECT CT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL SPECT CT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL BIOCHEMICAL RECURRENCE DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL BIOCHEMICAL RECURRENCE DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL BIOCHEMICAL RECURRENCE DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL INITIAL STAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL INITIAL STAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL INITIAL STAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL TREATMENT MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL TREATMENT MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL ACADEMIC RESEARCH INSTITUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL ACADEMIC RESEARCH INSTITUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL ACADEMIC RESEARCH INSTITUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL DIAGNOSTIC CENTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL DIAGNOSTIC CENTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL DIAGNOSTIC CENTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 64. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 65. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 66. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 67. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 68. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 69. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 70. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 71. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 72. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 73. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 74. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 75. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 76. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 77. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 78. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 79. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 80. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 81. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 82. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 83. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 84. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 85. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 86. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 87. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 88. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 89. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 90. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 91. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 92. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 93. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 94. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 95. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 96. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 97. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 98. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 99. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 100. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 101. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 102. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 103. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 104. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 105. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 106. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 107. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 108. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 109. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 110. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 111. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 112. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 113. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 114. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 115. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 116. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 117. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 118. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 119. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 120. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 121. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 122. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 123. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 124. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 125. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 126. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 127. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 128. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 129. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 130. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 131. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 132. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 133. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 134. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 135. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 136. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 137. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 138. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 139. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 140. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 141. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 142. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 143. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 144. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 145. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 146. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 147. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 148. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 149. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 150. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 151. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 152. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 153. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 154. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 155. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 156. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 157. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 158. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 159. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 160. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 161. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 162. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 163. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 164. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 165. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 166. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 167. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 168. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 169. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 170. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 171. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 172. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 173. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 174. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 175. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 176. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 177. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 178. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 179. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 180. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 181. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 182. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 183. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 184. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 185. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 186. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 187. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 188. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 189. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 190. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 191. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 192. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 193. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 194. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 195. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 196. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 197. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 198. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 199. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 200. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 201. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 202. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 203. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 204. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 205. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 206. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 207. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 208. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 209. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 210. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 211. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 212. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 213. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 214. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 215. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 216. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 217. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 218. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 219. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 220. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 221. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 222. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 223. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 224. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 225. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 226. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 227. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 228. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 229. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 230. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 231. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 232. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 233. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 234. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 235. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 236. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 237. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 238. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 239. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 240. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 241. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 242. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 243. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 244. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 245. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 246. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 247. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 248. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 249. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 250. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 251. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 252. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 253. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 254. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 255. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 256. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 257. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 258. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 259. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 260. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 261. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 262. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 263. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 264. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 265. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 266. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 267. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 268. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 269. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 270. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 271. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 272. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 273. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 274. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 275. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 276. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
• TABLE 277. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 278. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
• TABLE 279. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
• TABLE 280. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 281. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)